EGLE THERAPEUTICS
Egle Therapeutics is an emerging biotechnology company focused on developing First-In-Class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases. The company was founded in 2020 and is based in Paris, France.
EGLE THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2020-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.egle-tx.com
Total Employee:
11+
Status:
Active
Contact:
+33-186640857
Email Addresses:
[email protected]
Total Funding:
40 M EUR
Technology used in webpage:
Microsoft Exchange Online
Similar Organizations
Immunscape AB
Immunscape is a privately held drug discovery focused on developing immunotherapies for cancer and autoimmune disease treatment.
Current Advisors List
Current Employees Featured
Founder
Investors List
Fund+
Fund+ investment in Series A - Egle Therapeutics
Takeda Ventures
Takeda Ventures investment in Series A - Egle Therapeutics
Life Sciences Partners
Life Sciences Partners investment in Series A - Egle Therapeutics
Bpifrance
Bpifrance investment in Series A - Egle Therapeutics
Bioqube Ventures
Bioqube Ventures investment in Series A - Egle Therapeutics
Official Site Inspections
http://www.egle-tx.com
- Host name: cluster020.hosting.ovh.net
- IP address: 46.105.57.169
- Location: Saint-Ouen France
- Latitude: 48.9067
- Longitude: 2.3339
- Timezone: Europe/Paris
- Postal: 93400
More informations about "Egle Therapeutics" on Search Engine
egle - Modulating Treg Cells to Balance Immunity
About Egle Therapeutics SAS (Egle) Egle Therapeutics is a biotechnology company focused on developing immunotherapies targeting suppressive regulatory T cells. Egle is …See details»
Egle Therapeutics | LinkedIn
Egle Therapeutics | 2,296 followers on LinkedIn. Modulating T-regulatory cells to balance immunity | Egle Therapeutics has been founded with a vision to become a game …See details»
Egle Therapeutics - Crunchbase Company Profile & Funding
Details. Egle Therapeutics is an emerging biotechnology company focused on developing First-In-Class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) …See details»
EGLE Therapeutics Strengthens its Leadership Team with the …
2 days ago PARIS, May 10, 2024--EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused …See details»
Egle Therapeutics Raises 40 Million - Business Wire
Oct 22, 2021 PARIS-- ( BUSINESS WIRE )-- Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In-Class immunotherapies targeting immune suppressor regulatory T-cells...See details»
Egle Therapeutics Strengthens its Leadership Team with the …
PARIS, March 27, 2024 -- ( BUSINESS WIRE )--Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused …See details»
Egle Therapeutics nabs $46M as it looks to push into the clinic …
By Ben Adams Oct 22, 2021 9:05am. autoimmune disease immunotherapy Oncology regulatory T cells. After launching last year and swiftly grabbing a Takeda deal, …See details»
Egle Therapeutics - EQT Group
Egle Therapeutics. Current portfolio. Egle Therapeutics. Egle is developing a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique …See details»
Egle Therapeutics Identifies First Novel Regulatory T-cell Targets …
Nov 26, 2020 PARIS-- ( BUSINESS WIRE )-- Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing first-in class immunotherapies …See details»
i-Lab 2020: Egle Therapeutics awarded for its …
On July 16th 2020, the i-Lab national innovation competition distinguished two projects from Institut Curie. Egle Therapeutics, the latest start-up created and supported by Institut Curie and AVATAR MEDICAL, a …See details»
Egle Therapeutics to present novel immunocytokine preclinical …
Apr 4, 2024 Egle Therapeutics is a biotechnology company focused on developing immunotherapies targeting suppressive regulatory T cells. Egle is leveraging a …See details»
Egle Therapeutics - Funding, Financials, Valuation & Investors
Egle Therapeutics has raised a total of. €40M. in funding over 1 round. This was a Series A round raised on Oct 22, 2021. Egle Therapeutics is funded by 6 investors. Fund+ and …See details»
Egle Therapeutics raises 40 million € Series A to develop First-In ...
Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In- Class immunotherapies targeting immune suppressor regulatory T …See details»
Egle Therapeutics Raises 40 Million - Financial Post
Oct 22, 2021 PARIS — Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In-Class immunotherapies targeting immune …See details»
Egle Therapeutics | VentureRadar
Mar 2, 2021 Founded in 2020. Private Company. Develops first-in-class immunotherapies targeting suppressor regulatory T cells for oncology and autoimmune diseases using …See details»
Egle Therapeutics to present novel immunocytokine preclinical …
Apr 4, 2024 Egle Therapeutics is a biotechnology company focused on developing immunotherapies targeting suppressive regulatory T cells. Egle is leveraging a …See details»
Egle Therapeutics – Startups.Bio
November 4, 2020. New Biotech Startups. Egle Therapeutics is a spin-out of Institut Curie in France, developing immunotherapies targeting suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases.See details»
Egle Therapeutics Raises 40 Million € Series a to Develop First-In ...
Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In-Class immunotherapies targeting immune suppressor regulatory T …See details»
Egle Therapeutics - Contacts, Employees, Board Members, …
Egle Therapeutics is a biotechnology company focused on developing immunotherapies for oncology and autoimmune diseases.See details»
Egle Therapeutics Raises 40 Million € Series a to Develop
Oct 22, 2021 PARIS-- ( BUSINESS WIRE )-- Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In-Class immunotherapies targeting …See details»